Asitri Dashboard Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Clinical Trials Search Results
Search History:
Count: 306
Selected: 0
| NCT ID | Title | ||
|---|---|---|---|
| NCT03056040 | ALXN1210 Versus Eculizumab in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Eculizumab | ||
| NCT03551730 | Phase 2 Healthy Volunteer Study to Evaluate the Ability of PRT064445 to Reverse the Effects of Several Blood Thinner Drugs on Laboratory Tests (Module 3 of 4) | ||
| NCT07306949 | Real-Life Clinical Efficacy of Acoramidis in Participants With ATTR-CM and Association With Cardiac Biomarkers | ||
| NCT06449001 | Study of Danicopan as Add-on Treatment to Ravulizumab or Eculizumab in Pediatric Participants With PNH Who Have Clinically Significant Extravascular Hemolysis | ||
| NCT01700179 | Evaluation of Safety, Tolerability, and Antiviral Activity of ACH-0143102 Plus Ribavirin In Treatment-naive Hepatitis C Virus Infection Genotype 1b Participants | ||
| NCT01757431 | The Safety and Efficacy of Eculizumab in Japanese Patients With Atypical Hemolytic Uremic Syndrome (aHUS) | ||
| NCT03403205 | Efficacy and Safety of ALXN1840 Administered for 48 Weeks Versus Standard of Care in Participants With Wilson Disease | ||
| NCT05966467 | Registry of Patients With AQP4+ NMOSD Treated With Alexion C5 Inhibitor Therapies | ||
| NCT04320602 | Ravulizumab in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria Currently Treated With High-Dose Eculizumab | ||
| NCT03748823 | Ravulizumab Subcutaneous (SC) Versus Ravulizumab Intravenous (IV) in Adults With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Eculizumab | ||
| NCT00935883 | Complement Inhibition With Eculizumab for the Treatment of Non-Exudative Macular Degeneration (AMD) | ||
| NCT03920293 | Safety and Efficacy Study of Ravulizumab in Adults With Generalized Myasthenia Gravis | ||
| NCT04256148 | ALXN1830 in Patients With Warm Autoimmune Hemolytic Anemia | ||
| NCT04469465 | Danicopan as Add-on Therapy to a C5 Inhibitor in Paroxysmal Nocturnal Hemoglobinuria (PNH) Participants Who Have Clinically Evident Extravascular Hemolysis (EVH)(ALPHA) | ||
| NCT03083704 | A Healthy Volunteer PK/PD, Safety and Tolerability Study of Second Generation Andexanet Alfa | ||
| NCT04451434 | Study of Danicopan in Participants of Japanese Descent | ||
| NCT01275287 | Targeting Complement Activation in Antineutrophil Cytoplasmic Autoantibodies (ANCA)-Vasculitis - Eculizumab | ||
| NCT01410916 | Safety and Efficacy Study of Eculizumab in Shiga-Toxin Producing Escherichia Coli Hemolytic-Uremic Syndrome (STEC-HUS) | ||
| NCT00040157 | Safety and Antiviral Study of ACH-126, 443 (Beta-L-Fd4C) in the Treatment of Adults With HIV Infection and Modestly Detectable Viral Load. | ||
| NCT01229254 | Evaluate the Pharmacokinetics and Safety of MK-4448 in Participants With Nonvalvular Atrial Fibrillation or Atrial Flutter | ||
| NCT01671956 | Evaluation of Safety, Efficacy, Pharmacokinetic and Pharmacodynamic of Bertilimumab in Patients With Active Moderate to Severe Ulcerative Colitis | ||
| NCT00088179 | Pexelizumab in Patients Undergoing Coronary Artery Bypass Grafting With Cardiopulmonary Bypass (PRIMO-CABG II) | ||
| NCT04581785 | Gene Therapy With hLB-001 in Pediatric Patients With Severe Methylmalonic Acidemia | ||
| NCT03369236 | A Proof-of-Concept Study of Danicopan for 6 Months of Treatment in Participants With C3 Glomerulopathy (C3G) | ||
| NCT07157787 | Study of ALXN1920 in Adult Participants With Primary Membranous Nephropathy (PMN) | ||
| NCT02345421 | A Study to Identify and Characterize LAL-D Patients in High-risk Populations | ||
| NCT03310021 | A Healthy Volunteer Pharmacokinetics (PK)/Pharmacodynamics (PD), Safety and Tolerability Study of Andexanet in Healthy Japanese and Caucasian Subjects | ||
| NCT05778071 | Evaluation of the Safety and Efficacy of Eneboparatide (AZP-3601) in Patients With Chronic Hypoparathyroidism | ||
| NCT05047458 | A Study of Single-dose ALXN2050 in Healthy Adults | ||
| NCT07221838 | A Study to Investigate OCS Tapering in Adult Participants With Generalized Myasthenia Gravis Treated With Ravulizumab | ||
| NCT04623710 | Study of ALXN2050 in Participants With Renal Impairment | ||
| NCT05428696 | Safety and Tolerability, PK, and PD Study of Single and Multiple ALXN2080 Doses in Healthy Participants | ||
| NCT00739505 | Safety Study of Human Recombinant Tissue Non-Specific Alkaline Phosphatase Fusion Protein Asfotase Alfa in Adults With Hypophosphatasia (HPP) | ||
| NCT04889391 | Study of Radiolabeled Danicopan in Healthy Male Participants | ||
| NCT01488097 | Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of SBC-102 (Sebelipase Alfa) in Adult Subjects With Lysosomal Acid Lipase Deficiency | ||
| NCT07037420 | ALXN2420 Versus Placebo in Combination With Somatostatin Analogs in Participants With Acromegaly | ||
| NCT01399593 | Safety & Efficacy of Eculizumab to Prevent AMR in Living Donor Kidney Transplant Recipients Requiring Desensitization | ||
| NCT06079359 | Phase 3 Study of ALXN1850 in Treatment-Naïve Pediatric Participants With HPP | ||
| NCT05884060 | Retrospective Chart Review Screening Algorithm to Assess the Prevalence of PNH-clones | ||
| NCT06744647 | Phase 2 Study of ALXN2030 in Patients With Antibody-Mediated Rejection After Kidney Transplantation | ||
| NCT05254613 | A Study of Single and Multiple SC Doses of ALXN1830 in Healthy Adult Participants | ||
| NCT04933682 | Drug Interaction Study of ALXN2050 With Fluconazole and Rifampin in Healthy Adult Participants | ||
| NCT03131219 | Study of Ravulizumab in Children and Adolescents With Atypical Hemolytic Uremic Syndrome (aHUS) | ||
| NCT05288816 | A Study of Single and Multiple Doses of ALXN1210 in Healthy, Adult Japanese Participants | ||
| NCT00380159 | Open-Label, 48-Week Extension Study of Elvucitabine in Combination With Background Antiretroviral Therapy (ART) for Participants Who Have Completed Study ACH443-014A | ||
| NCT02207725 | A Study in Older Subjects to Evaluate the Safety and Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of Apixaban | ||
| NCT01106027 | Dosing Regimen of Eculizumab Added to Conventional Treatment in Positive Crossmatch Deceased Donor Kidney Transplant | ||
| NCT02226146 | Evaluation of Safety, Efficacy and Pharmacodynamic Effect of Bertilimumab in Patients With Bullous Pemphigoid | ||
| NCT01419028 | A Retrospective Study of the Natural History of Patients With Severe Perinatal and Infantile Hypophosphatasia (HPP) | ||
| NCT00350272 | Elvucitabine/Efavirenz/Tenofovir Versus Lamivudine/Efavirenz/Tenofovir in Human Immunodeficiency Virus (HIV)-1 Infected, Treatment-naive Participants |
